Sangamo BioSciences has received a $6.4 million Strategic Partnership Award from California Institute for Regenerative Medicine to use its zinc finger nuclease gene-editing technology in hematopoietic stem cells to develop a potential ZFP Therapeutic for beta-thalassemia. The four-year grant provides matching funds for preclinical work to support ... (more)
http://www.contractpharma.com/contents/view_breaking-news/2013-05-24/sangamo-biosciences-cirm-in-strategic-pact/
http://www.contractpharma.com/contents/view_breaking-news/2013-05-24/sangamo-biosciences-cirm-in-strategic-pact/
No comments:
Post a Comment